Caribou Biosciences presents car-t updates at healthcare conference

16 Mwezi wa tano, 2026

Imeripotiwa na AI

Caribou Biosciences discussed progress on its off-the-shelf CAR-T therapies during a presentation at the Bank of America Global Healthcare Conference on May 13. Chief executive Rachel Haurwitz highlighted Phase I data for two programs that target lymphoma and multiple myeloma.

The company is advancing Vispa-cel, which targets CD19 for lymphoma, and CB-011, which targets BCMA for multiple myeloma. Both programs received significant clinical updates late last year, and early results support best-in-class potential, Haurwitz said during the session moderated by analyst Alec Stranahan.

Makala yanayohusiana

Illustration of a German woman achieving complete remission from three autoimmune diseases via groundbreaking CAR-T therapy, symbolizing hope and medical triumph.

CAR-T therapy achieves complete remission of three autoimmune diseases in German woman

9 Mwezi wa nne, 2026 Imeripotiwa na AI Picha iliyoundwa na AI

A 47-year-old woman bedridden with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome has achieved complete remission after CAR-T cell therapy at University Hospital Erlangen in Germany. Treated by Fabian Müller after nine failed therapies, she recovered rapidly and remains healthy over a year later without medication—the first simultaneous treatment of multiple autoimmune diseases with this method.

CAR-T cell therapy shows early promise for HIV control

A small study has found that CAR-T cell therapy may offer a new way to manage HIV over the long term. The approach, already used to treat certain cancers, involves engineering a patient’s own immune cells.

Bioinvent hosts kol event on ovarian cancer therapies

1 Mwezi wa sita, 2026 Imeripotiwa na AI

BioInvent International AB held a key opinion leader event on May 27, 2026, to discuss ovarian cancer treatments and TNFR2-targeted therapies.

Business

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Europe

CRIS Cancer to donate 3.6 million to Vega Oncotargets after controversy

Business

Syntara reports positive FDA feedback on amsulostat trial

Scientists develop antibodies to block widespread Epstein-Barr virus

Researchers at Fred Hutch Cancer Center have created human-like monoclonal antibodies that prevent Epstein-Barr virus (EBV) from infecting immune cells. Using mice engineered with human antibody genes, the team identified antibodies targeting viral proteins gp350 and gp42, with one fully blocking infection in lab models. The findings, published in Cell Reports Medicine, could lead to therapies for transplant patients at risk of EBV-related complications.

Oncolys president reflects on journey to world-first cancer treatment

18 Mwezi wa sita, 2026 Imeripotiwa na AI

Yasuo Urata, president of Oncolys BioPharma, reflected on the long development process after the company received approval for a viral therapy targeting esophageal cancer.

Alhamisi, 25. Mwezi wa sita 2026, 15:16:17